This is an amended filing
Alteogen Inc. Alteogen Biologics merger schedule changed, shareholder meeting moved to January 15, 2027
AAI summary · Not investment advice
Alteogen will absorb Alteogen Biologics at a ratio of 1 : 0.1679581, with the shareholder meeting moved to January 15, 2027 and the merger date to February 16, 2027.
Key facts
- Merger date
- Feb 16, 2027As corrected
- Appraisal rights period
- Within 20 days from the shareholders' meeting resolution dateWithin 20 days from the shareholders' meeting resolution date
- % of total assets
- 12.71%Relative to the controlling company's consolidated total assets
- Purpose of merger
- Secure financial stability, mitigate business and financial risks, improve operating efficiency, and build a fully integrated FIBCO business system
- Shareholders' meeting date
- Jan 15, 2027As corrected
- Board resolution date
- Oct 6, 2026
Commentary
AI commentary · Not investment advice
What happened
Altogether Biologics Co., Ltd. (Altogether Biologics) will be absorbed by its parent, Alteogen Inc., and will cease to exist. In this absorption merger (one company takes over another, and the taken-over company disappears), Alteogen is the surviving company. Alteogen is also the largest shareholder. The merger will create 600,477 new common shares. The stated purposes are financial stability, lower business and financial risk, a restructuring for operating efficiency, and a fully integrated FIBCO business system. The merger ratio is 1 : 0.1679581.
In the company's terms
Altogether Biologics' total assets equal 12.71% of the controlling company's consolidated total assets. Alteogen, the merging company, had sales of KRW 202.829 billion in its 2025 year-end separate financial statements. Its net income (the final profit after taxes and other costs) was KRW 125.482 billion on the same basis.
What changes for shareholders
This correction changed the schedule. The shareholders' meeting is on 2027.01.15. The period to apply to sell shares back to the company (appraisal rights) is within 20 days of the meeting's vote date. These rights apply to Altogether Biologics shareholders who oppose the merger. Creditors can raise objections from 2027.01.15 to 2027.02.15. The merger date is 2027.02.16. Merger registration is scheduled for 2027.02.17.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist